CLINICAL TRIALS PROFILE FOR DOXAPRAM HYDROCHLORIDE

All Clinical Trials for Doxapram Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00088738 ↗	Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ	Completed	National Institute of Mental Health (NIMH)	Phase 1	2004-07-27	This study is designed to observe the effects of a panic attack in patients with panic disorders and to demonstrate the involvement of Substance P in panic disorder, and thereby, further our understanding of its role in this illness. We will measure levels of Substance P in the brain by obtaining pictures of the brain using PET and MRI....
NCT00389909 ↗	Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants	Completed	Jean Michel Hascoet	Phase 4	2006-11-01	Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of this study is to compare a dosage regimen based only on patient's weight, to another one using a dosing chart taking into account weight, age and gender.
NCT00389909 ↗	Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants	Completed	Maternite Regionale Universitaire	Phase 4	2006-11-01	Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two factors are linked to these fluctuations: age and gender. The aim of this study is to compare a dosage regimen based only on patient's weight, to another one using a dosing chart taking into account weight, age and gender.
NCT00477451 ↗	Staccato Alprazolam in Panic Attack	Completed	Alexza Pharmaceuticals, Inc.	Phase 2	2007-05-01	We are developing Staccato™ Alprazolam for the treatment of Panic attacks associated with panic disorder. This study will provide an initial assessment of efficacy, and to continue to describe the tolerability and pharmacokinetics, of a single inhaled dose of Staccato Alprazolam on a doxapram-induced panic attack in patients with panic disorder.
NCT01022151 ↗	Aminophylline and Cognitive Function After Sevoflurane Anaesthesia	Completed	King Faisal University	Phase 2	2007-11-01	Early postoperative recovery of neurologic and cognitive functions is especially advantageous after fast-tracking ambulatory procedures to hasten home discharge after surgery.1 It is well known that volatile anaesthetic agents may generate adverse postoperative cognitive effects and even traces of it may affect task performance in healthy volunteers.2Hence, rapid elimination of the volatile anaesthetics may help reduce postoperative confusion and cognitive impairment in surgical patients by facilitating a faster recovery from general anaesthesia.3 Sevoflurane has been advocated for the routine anesthesia for ambulatory surgery patients. It activates adenosine A1 receptors in primary rat hippocampal cultures through the liberation of adenosine secondary to the interaction of with adenosine transport or key enzymes in adenosine metabolism.4 However; sevoflurane anaesthesia is associated with slower emergence and delayed early postoperative cognitive recovery than desflurane5 and xenon2 anaesthesia. Aminophylline, which is a hydrophilic cyclic adenosine mono-phosphate (cAMP) dependent phosphodiesterase inhibitor has been used for long time to antagonize the sedative effects of morphine, diazepam, and barbiturates.6-7Aminophylline in doses of 2-5 mg/kg shortens the recovery from sevoflurane anaesthesia and improves bispectral index scores (BIS) with concurrent increases in heart rate which might have a detrimental effect in patients with ischaemic heart disease.8-11However, the use of smaller doses of 2-3 mg/kg is associated with less increases in heart rate. 10-11 The use of 1 mg/kg of Doxapram is comparable to 2 mg/kg of aminophylline in improvement of early recovery from sevoflurane anaesthesia secondary to its central nervous system stimulating effect rather than increased ventilatory elimination of sevoflurane.11 Currently, there is no available published studies have investigated the effects of either theophylline or doxapram on early postoperative cognitive recovery after balanced anaesthesia with sevoflurane. We hypothesized that the use of small doses of aminophylline [2-3 mg/kg] may be comparable to larger doses in improvement of the early postoperative cognitive recovery from sevoflurane anaesthesia with associated non-significant increases in heart rate. The present study investigated the effects of 1 mg/kg of doxapram, and 2, 3, 4, and 5 mg/kg of aminophylline on the early postoperative cognitive recovery using the Short Orientation Memory Concentration Test (SOMCT), response entropy (RE) state entropy (SE), difference between RE and SE (RE-SE), end-tidal sevoflurane concentration, haemodynamics, the times to eyes opening and to extubation and degree of sedation after sevoflurane anaesthesia in patients undergoing ambulatory surgery.

Clinical Trial Conditions for Doxapram Hydrochloride

Condition Name

Condition Name for Doxapram Hydrochloride
Intervention	Trials
Postoperative Shivering	2
Healthy	2
Administration of Caffeine in the Delivery Room	1
Postoperative Confusion	1

Condition MeSH

Condition MeSH for Doxapram Hydrochloride
Intervention	Trials
Panic Disorder	2
Confusion	1
Respiratory Insufficiency	1
Disease	1

Clinical Trial Locations for Doxapram Hydrochloride

Trials by Country

Trials by Country for Doxapram Hydrochloride
Location	Trials
Netherlands	7
Belgium	5
Egypt	5
United States	3
China	1

Trials by US State

Trials by US State for Doxapram Hydrochloride
Location	Trials
Ohio	1
New York	1
Maryland	1

Clinical Trial Progress for Doxapram Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Doxapram Hydrochloride
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for Doxapram Hydrochloride
Clinical Trial Phase	Trials
Completed	6
Unknown status	4
Recruiting	3

Clinical Trial Sponsors for Doxapram Hydrochloride

Sponsor Name

Sponsor Name for Doxapram Hydrochloride
Sponsor	Trials
Beni-Suef University	2
University of Florence	1
Kasr El Aini Hospital	1

Sponsor Type

Sponsor Type for Doxapram Hydrochloride
Sponsor	Trials
Other	16
NIH	2
Industry	2

Doxapram Hydrochloride Market Analysis and Financial Projection

Last updated: April 27, 2026

Doxapram Hydrochloride: Clinical Trials Update, Market Analysis, and Projections

Doxapram hydrochloride is a respiratory stimulant with a long clinical footprint and a constrained, treatment-specific market profile. No current, credible global late-stage (Phase 2/3) development pipeline is evidenced in publicly indexed trial registries for new drug products using doxapram hydrochloride itself. The practical commercial outlook therefore rests on (1) existing supply and label-driven use in acute care settings, (2) competitive substitution by older respiratory stimulants and non-drug respiratory management, and (3) region-by-region regulatory access.

---

What is the clinical-trials status for doxapram hydrochloride?

Trial activity: public signal

Across standard public registries used by industry (e.g., ClinicalTrials.gov and WHO ICTRP), doxapram hydrochloride does not show a visible, ongoing Phase 2 or Phase 3 program that would support a new global product-cycle based on registrable clinical outcomes. The observable footprint is characterized by legacy and small studies that do not translate into a near-term, trial-driven catalyst.

Regulatory-grade inference from trial design

Where new evidence does surface for doxapram, it typically aligns to one of these patterns:

• Comparative or adjunctive studies in controlled clinical settings
• Narrow indications tied to respiratory depression syndromes or monitoring protocols
• Product-form or dosing strategy studies rather than “new MOA” development

These patterns do not create a broad late-stage catalyst profile typical of large market expansion programs.

Clinical development implication

For investors and R&D planners, the absence of a registrable late-stage pipeline means the primary question is not “when approval follows trials,” but “whether supply, label access, and procurement economics sustain demand.”

---

Where does doxapram hydrochloride sit in the treatment pathway?

Core use pattern

Doxapram hydrochloride is used to stimulate breathing in specific clinical contexts involving respiratory depression. In real-world hospital practice, adoption is mediated by:

• ICU and step-down protocols for acute respiratory failure phenotypes
• Neonatal intensive care pathways in selected markets (where historically used)
• Emergency and peri-procedural respiratory support protocols (region-dependent)
• Availability and procurement of injectable products

Mechanism and practical constraint

The drug’s value proposition is anchored to short-horizon respiratory stimulation, not chronic disease management. That compresses addressable demand into acute-episode volumes and formulary access cycles.

---

What does the market look like for doxapram hydrochloride today?

Market structure

The doxapram market is shaped by:

• Tender- and hospital-procurement dynamics rather than outpatient repeat prescriptions
• Volumes that track acute respiratory event incidence and local clinical guideline adoption
• Regulatory variability by country (legacy products often remain accessible but face periodic manufacturing and supply challenges)

Demand drivers

The near-term commercial demand is driven by:

• Hospital bed occupancy and acute care utilization
• Protocol preferences for respiratory stimulants versus alternative interventions
• Product availability, pricing, and switching costs in formularies

Key headwinds

• Substitution by alternative respiratory management approaches
• Supplier concentration risk and pricing pressure in generics markets
• Limited visibility of new-label expansion supported by late-stage clinical programs

Competitive landscape (functional substitution)

Competition is less about another single branded drug with equivalent uptake and more about:

• Hospital protocols where drug-based stimulation is deprioritized relative to ventilation and monitoring
• Generics or older respiratory stimulants where permitted
• Non-pharmacologic or device-based approaches

---

What market data supports projections?

Projection framework

Given the lack of a visible late-stage pipeline catalyst, projections should be treated as a “steady-state with procurement volatility” model:

1) Baseline volume: Acute-care respiratory depression episodes treated with stimulant use 2) Formulary persistence: Existing hospital procurement and label access continuity 3) Supply elasticity: Manufacturing uptime, distribution reach, and tender cycles 4) Price discipline: Competitive tender pricing and generic erosion

Scenario model (directional)

Using a steady-state framework, three scenarios apply:

Base case (most likely):

• Demand remains tied to existing clinical use
• Price stays under pressure from generics and tender bidding
• Revenue growth tracks inflation and modest volume fluctuations

Downside case:

• Supply disruptions or quality events reduce availability
• Hospitals switch away due to procurement and protocol changes
• Revenue declines due to reduced access and lower utilization

Upside case:

• Region-by-region guideline reinforcement sustains stimulant use
• New tender cycles restore favorable pricing
• Occasional supplemental procurement after supply shortages stabilize

---

How should R&D and investment decisions be structured?

R&D where value can still be created

Because late-stage development appears absent at scale, “new value” typically comes from:

• Product lifecycle management (stable supply, formulation assurance)
• Evidence generation aligned to specific induction protocols or niche populations
• Label refinement efforts that improve procurement access rather than broad indication expansion

Non-development levers

Commercial execution dominates:

• Contracting strategy with hospital networks
• Forecasting tender windows and manufacturing planning
• Ensuring consistent supply lead times to protect formulary retention

---

What is the practical outlook for 2026 to 2031?

Market projection (investment-relevant)

Without a late-stage pipeline catalyst, the market outlook is dominated by baseline demand and procurement economics. Expected performance profile:

• Low-to-moderate revenue growth driven by inflation and episodic volume changes
• High sensitivity to supply availability, manufacturing continuity, and tender pricing
• Limited step-change upside unless a new clinical or regulatory expansion materializes

Operational KPIs to monitor

• Country-level tender outcomes and formulary retention
• Manufacturing batch consistency and distribution coverage
• Price index movements in hospital procurement for injectable respiratory stimulants
• Substitution signals in clinical protocol updates

---

Key Takeaways

• Doxapram hydrochloride shows no visible, registrable late-stage (Phase 2/3) development catalyst in public clinical trial sources, limiting near-term growth tied to new approvals.
• The market remains acute-care and protocol-driven, with demand shaped by hospital procurement and availability rather than chronic-use expansion.
• Projections should be modeled as steady-state revenue with procurement volatility, where supply continuity and tender pricing govern outcomes.
• Upside depends on region-specific guideline persistence or label access improvements; downside risk centers on switching and supply disruptions.

---

FAQs

1) Is there an active Phase 2 or Phase 3 development program for doxapram hydrochloride?
Public trial registries do not show a clear, ongoing late-stage program for doxapram hydrochloride that would indicate a near-term approval-driven catalyst.

2) What drives demand for doxapram hydrochloride commercially?
Demand is tied to acute respiratory depression treatment episodes and hospital formularies, with procurement cycles and product availability acting as primary levers.

3) What are the biggest competitive pressures?
Functional substitution by alternative respiratory management approaches and tender-driven generic competition are the main competitive forces.

4) How should forecasts be structured for doxapram hydrochloride?
Use a steady-state baseline volume model with scenario-based adjustments for tender pricing and supply continuity rather than assuming pipeline-driven acceleration.

5) What would change the market trajectory most?
A new regulatory label expansion or a registrable late-stage development outcome could create step-change demand; absent that, the market is predominantly procurement and supply-driven.

---

References (APA)

[1] ClinicalTrials.gov. (n.d.). Search results for doxapram hydrochloride. https://clinicaltrials.gov/
[2] WHO International Clinical Trials Registry Platform (ICTRP). (n.d.). Doxapram hydrochloride search. https://trialsearch.who.int/
[3] U.S. National Library of Medicine. (n.d.). Doxapram hydrochloride information and related records. https://pubmed.ncbi.nlm.nih.gov/